Therapy Light Rooms for Improved Sleep in Dementia Patients

Dementia Clinical Trial

— DEMLIGHT  

Official title:

Therapy Light Rooms for Nursing Home Patients With Dementia - Designing Diurnal Conditions for Improved Sleep, Mood and Behavioural Problems (DEM.LIGHT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03357328
• Other study ID #: UBergenDEM.LIGHT
• Secondary ID: 2016/2246
• Status: Completed
• Phase: N/A
• Start date: September 25, 2017
• Est. completion date: April 24, 2018

Study information

• Verified date: May 2018
• Source: University of Bergen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This intervention study will investigate the effect of therapy light rooms on sleep, circadian rhythms, mood, behavioural problems and function in nursing home (NH) patients with dementia.

Description:

People with dementia often have fragmented night-time sleep, prolonged night-time awakenings and increased daytime sleep. Behavioural and psychological symptoms of dementia (BPSD) (e.g. agitation, depression) are also common. Noticeably, both sleep problems and BPSD are related to a disturbed circadian rhythm. Light is the most important input to the circadian system, and exposure to sufficient daylight is important for entrainment of the circadian rhythm to the surroundings. Dementia patients living in nursing homes (NH) are less exposed to daylight than dementia patients living at home. Bright light therapy is a promising treatment in these patients as it may improve sleep, BPSD, and independent functioning. However, traditional bright light treatment has not been routinely employed in NH patients or patients with dementia. This may be related to difficulties in achieving adherence to the traditional treatment and thus the benefit of bright light therapy for people with dementia still remains unclear.

DEM.LIGHT uses modern LED (light-emitting diodes) technology that enables light therapy with the least possible interference of the day-to-day life in NHs, as the treatment is not confined to a light source presupposing behavioural compliance. Ceiling-mounted LED-sources can be programmed in terms of timing, light intensity and colour temperature. DEM.LIGHT uses this to provide therapy light rooms with a dynamic light condition that better emulates natural light throughout the day. The study is a cluster-randomized trial evaluating the effect of therapy light rooms on various measures of physical and mental health in NH patients with dementia. Data will be collected at baseline, after 8 and 16 weeks of treatment, and at the end of the intervention period (24 weeks).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: April 24, 2018
• Est. primary completion date: April 21, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• 60 years or more of age and in long term care (longer than 4 weeks)

• have dementia in accordance with DSM-V

• have either sleep/circadian rhythm disturbances, BPSD as identified by NPI-NH, or severely reduced ADL function

• provide written informed consent if the participant has capacity, if not, a written proxy informed consent from a legally authorized representative

Exclusion Criteria:

• are blind or may otherwise not benefit from light

• partake in another trial

• have a condition contra-indicated to the intervention

• have an advanced, severe medical disease/disorder and/or expected survival of less than 6 months or other aspects that could interfere with participation

• are psychotic or have a severe mental disorder

Related Conditions & MeSH terms

• Alzheimer Disease
• Behavioural and Psychiatric Symptoms of Dementia
• Dementia
• Sleep Deprivation
• Sleep Fragmentation

Intervention

Other:
• Therapy light room
See group description
• Standard light
See group description

Locations

Country	Name	City	State
Norway	University of Bergen	Bergen	Hordaland

Sponsors (1)

Lead Sponsor	Collaborator
University of Bergen

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in actigraphy recorded sleep and circadian rhythm	An actigraph (Actiwatch 2, Philips Respironics) is worn for 7 consecutive days	Baseline and week 8, 16, and 24
Primary	Change in proxy-rated sleep	Sleep Disorders Inventory (a proxy-rated instrument) is completed. A total score is calculated from the product of the average frequency and average severity of seven symptoms. The total score ranges from 0 (best) to 12 (worst).	Baseline and week 8, 16, and 24
Primary	Change in circadian rhythm of core body temperature	A swallowed capsule (e-Celsius, BodyCap) records core body temperature for 24 hours.	Baseline and week 8, 16, and 24
Secondary	Change in the Neuropsychiatric Inventory - Nursing Home version (NPI-NH)	NPI-NH is a proxy-rated instrument to assess neuropsychiatric disturbances in people with dementia. A total score is calculated from the product of the frequency and severity of 12 items. The total score ranges from 0 (best) to 144 (worst).	Baseline and week 8, 16 and 24
Secondary	Change in the Cohen-Mansfield Agitation Inventory (CMAI)	CMAI is a proxy-rated instrument measuring agitation symptoms. The instrument has 29 items, and the total score ranges from 29 (best) to 203 (worst).	Baseline and week 8, 16 and 24
Secondary	Change in the Cornell Scale of Depression in Dementia (CSDD)	CSDD is a proxy-rated instrument addressing depression in people with dementia. The instrument has 19 items, and the total score ranges from 0 (best) to 38 (worst).	Baseline and week 8, 16 and 24
Secondary	Change in the Quality of Life in Late-Stage Dementia (QUALID)	QUALID is a proxy-rated instrument validated for use in people with dementia. 11 behaviours are rated on a 5-point Likert scale, and the total score ranges from 11 (best) to 55 (worst).	Baseline and week 8, 16 and 24
Secondary	Change in the Mobilization-Observation-Behaviour-Intensity-Dementia 2 (MOBID-2)	MOBID-2 is a proxy-rated instrument to assess pain in people with dementia. The instrument consists of two parts, each with five items. In part 1, pain intensity is inferred by the patient's pain behaviours during standardized, guided movements. In part 2, pain intensity is assessed by the patient's pain behaviours related to internal organs, head, and skin. A total score, ranging from 0-10, is set based on an overall assessment of the pain intensity scores in part 1 and 2.	Baseline and week 16 and 24
Secondary	Change in the Mini Mental State Examination (MMSE)	MMSE is a cognitive function screening instrument, which discerns severity of cognitive impairment on a 30 point scale. Lower scores represent severe impairment.	Baseline and week 24
Secondary	Change in the Functional Assessment Staging (FAST)	FAST is a proxy-rated instrument validated for use in people with dementia. It ascertains the severity of dementia in seven stages of functioning.	Baseline and week 8, 16 and 24.
Secondary	Change in the Physical Self-Maintenance Scale	Physical Self-Maintenance Scale assesses Activities of Daily living (ADL) pertaining to physical function. The scale consists of six items, and the total score ranges from 0 to 30. Lower values indicate better functioning.	Baseline and week 8, 16 and 24
Secondary	Clinical Global Impression of Change (CGIC)	Rates globally perceived improvement ranging from very much worse (0) to very much improved (6). From baseline to week 8, 16 and 24.	Week 8, 16 and 24
Secondary	Change in the Resource Utilization in Dementia - Formal Care (RUD-FOCA)	RUD-FOCA is a cost-analysis of time invested in care during 24 hours	Baseline and week 8, 16 and 24
Secondary	Change in general health	The medical journal will be used to register change in total use of medication, blood pressure, pulse, weight and diagnoses.	Baseline and week 8, 16 and 24
Secondary	Change in burden of care	The NPI-NH total disruptiveness score is calculated by adding the occupational disruptiveness scores for the 12 items of the NPI-NH (each scored 0-5). The total disruptiveness score has a range of 0-60, with higher values representing more occupational disruptiveness.	Baseline and week 8, 16 and 24
Secondary	Change in staff alertness	Karolinska Sleepiness Scale comprises a single item assessing state sleepiness on a scale from 1 (very alert) to 9 (very sleepy, fighting sleep).	Baseline and week 8, 16 and 24
Secondary	Change in staff sleep	Bergen Insomnia Scale consists of six items. Each item is scored from 0 to 7, according to the number of days per week a specific insomnia symptom has occurred during the last month. The total score ranges from 0-42.	Baseline and week 8, 16 and 24
Secondary	Change in staff fatigue	The Chalder Fatigue Questionnaire has 13 items. The first 11 items (scored 0-3) are used to calculate a total score with a range from 0-33. Higher values represent more fatigue.	Baseline and week 8, 16 and 24
Secondary	Change in staff mental health	Measured by Hospital Anxiety and Depression Scale (HADS). HADS consists of two subscales, one for anxiety and one for depression, each with 7 items. The subscale scores range from 0 to 21. Higher values represent worse mental health (anxiety/depression).	Baseline and week 8, 16 and 24
Secondary	Change in staff health related quality of life	The SF-12 health survey consists of 12 items. Two summary scores (the Mental Health Component Summary and the Physical Health Component Summary) are calculated based on an algorithm from the User's Manual for the SF-12 Health Survey.	Baseline and week 8, 16 and 24